205178-80-9Relevant articles and documents
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
Ragusa, Giulio,Gómez-Ca?as, María,Morales, Paula,Rodríguez-Cueto, Carmen,Pazos, María R.,Asproni, Battistina,Cichero, Elena,Fossa, Paola,Pinna, Gerard A.,Jagerovic, Nadine,Fernández-Ruiz, Javier,Murineddu, Gabriele
, p. 398 - 412 (2017)
In the last few years, cannabinoid type-2 receptor (CB2R) selective ligands have shown a great potential as novel therapeutic drugs in several diseases. With the aim of discovering new selective cannabinoid ligands, a series of pyridazinone-4-c
NOVEL ARYL-CYANOGUANIDINE COMPOUNDS
-
Page/Page column 55, (2016/07/05)
The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2/s
3-O-Substituted benzyl pyridazinone derivatives as COX inhibitors
Chintakunta, Vamsee Krishna,Akella, Venkateswarlu,Vedula, Manohar Sharma,Mamnoor, Prem Kumar,Mishra, Parimal,Casturi, Seshagiri Rao,Vangoori, Akhila,Rajagopalan, Ramanujam
, p. 339 - 347 (2007/10/03)
New 3-O-substituted benzyl pyridazinone compounds have been synthesised and evaluated for their cyclooxygenase inhibitory activity and COX-2 selectivity. Among the compounds synthesised, three compounds (11b-11d) have shown in vitro COX-2 selectivity. These compounds have been evaluated for their in vivo potential using carrageenan-induced rat paw edema assay. One compound (11b) showed 32% anti-inflammatory activity at 30 mg kg-1 dose.